

Bastian Hengerer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6133836/publications.pdf>

Version: 2024-02-01

81
papers

7,020
citations

81900

39
h-index

69250

77
g-index

85
all docs

85
docs citations

85
times ranked

8795
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional ultrasound imaging of recent and remote memory recall in the associative fear neural network in mice. <i>Behavioural Brain Research</i> , 2022, 428, 113862.	2.2	5
2	Impact of Fkbp5 \bar{A} — early life adversity \bar{A} — sex in humanised mice on multidimensional stress responses and circadian rhythmicity. <i>Molecular Psychiatry</i> , 2022, 27, 3544-3555.	7.9	7
3	<i>FKBP5</i> polymorphisms induce differential glucocorticoid responsiveness in primary CNS cells â€œ First insights from novel humanized mice. <i>European Journal of Neuroscience</i> , 2021, 53, 402-415.	2.6	15
4	Activation of the medial preoptic area (MPOA) ameliorates loss of maternal behavior in a <i>Shank2</i> mouse model for autism. <i>EMBO Journal</i> , 2021, 40, e104267.	7.8	16
5	Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes. <i>Cells</i> , 2021, 10, 1442.	4.1	0
6	P.0696 Nuclei RNAseq reveals transcriptional alterations of prefrontal cortex astrocytes in a subpopulation of suicide completers.. <i>European Neuropsychopharmacology</i> , 2021, 53, S509-S510.	0.7	0
7	Role of the medial prefrontal cortex in the effects of rapid acting antidepressants on decision-making biases in rodents. <i>Neuropsychopharmacology</i> , 2020, 45, 2278-2288.	5.4	11
8	Cross-site Reproducibility of Social Deficits in Group-housed BTBR Mice Using Automated Longitudinal Behavioural Monitoring. <i>Neuroscience</i> , 2020, 445, 95-108.	2.3	13
9	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 144.	4.8	20
10	RFID-supported video tracking for automated analysis of social behaviour in groups of mice. <i>Journal of Neuroscience Methods</i> , 2019, 325, 108323.	2.5	41
11	The reverse translation of a quantitative neuropsychiatric framework into preclinical studies: Focus on social interaction and behavior. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 96-111.	6.1	19
12	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. <i>Journal of Psychiatric Research</i> , 2019, 113, 137-140.	3.1	81
13	Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model. <i>Molecular Neurobiology</i> , 2019, 56, 5111-5121.	4.0	3
14	Oligodendrocyte gene expression is reduced by and influences effects of chronic social stress in mice. <i>Genes, Brain and Behavior</i> , 2019, 18, e12475.	2.2	46
15	Chronic Social Stress Leads to Reduced Gustatory Reward Salience and Effort Valuation in Mice. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 134.	2.0	18
16	Altered dopaminergic regulation of the dorsal striatum is able to induce tic-like movements in juvenile rats. <i>PLoS ONE</i> , 2018, 13, e0196515.	2.5	27
17	Aripiprazole Selectively Reduces Motor Tics in a Young Animal Model for Touretteâ€™s Syndrome and Comorbid Attention Deficit and Hyperactivity Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 59.	2.4	13
18	Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice. <i>PLoS ONE</i> , 2018, 13, e0191225.	2.5	94

#	ARTICLE	IF	CITATIONS
19	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. <i>Expert Review of Proteomics</i> , 2017, 14, 499-514.	3.0	26
20	Novel Blood-Based Biomarkers of Cognition, Stress, and Physical or Cognitive Training in Older Adults at Risk of Dementia: Preliminary Evidence for a Role of BDNF, Irisin, and the Kynurenine Pathway. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1097-1111.	2.6	68
21	Tracing investment in drug development for Alzheimer disease. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 819-819.	46.4	45
22	Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal 1H-NMR spectroscopy study at 11.7T. <i>Translational Psychiatry</i> , 2017, 7, e1189-e1189.	4.8	16
23	738. Evidence from Gene-Environment Mouse Models that Amygdala Oligodendropathy Contributes to Emotional Pathology. <i>Biological Psychiatry</i> , 2017, 81, S299.	1.3	0
24	Proteasome impairment by $\hat{\pm}$ -synuclein. <i>PLoS ONE</i> , 2017, 12, e0184040.	2.5	49
25	LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain. <i>Bioanalysis</i> , 2016, 8, 1903-1917.	1.5	113
26	Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. <i>Acta Neuropathologica</i> , 2016, 131, 379-391.	7.7	140
27	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. <i>Acta Neuropathologica</i> , 2016, 132, 391-411.	7.7	116
28	Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase. <i>Brain, Behavior, and Immunity</i> , 2016, 54, 59-72.	4.1	103
29	CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 125-140.	4.1	31
30	Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. <i>Acta Neuropathologica</i> , 2014, 128, 651-663.	7.7	216
31	Identification and Affinity-Quantification of $\hat{\pm}$ -Amyloid and $\hat{\pm}$ -Synuclein Polypeptides Using On-Line SAW-Biosensor-Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2014, 25, 1472-1481.	2.8	14
32	Trifluoperazine rescues human dopaminergic cells from wild-type $\hat{\pm}$ -synuclein-induced toxicity. <i>Neurobiology of Aging</i> , 2014, 35, 1700-1711.	3.1	48
33	Mouse social stress induces increased fear conditioning, helplessness and fatigue to physical challenge together with markers of altered immune and dopamine function. <i>Neuropharmacology</i> , 2014, 85, 328-341.	4.1	92
34	ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?. <i>Journal of Neuroscience Methods</i> , 2013, 214, 62-68.	2.5	10
35	Nondopaminergic Neurotransmission in the Pathophysiology of Tourette Syndrome. <i>International Review of Neurobiology</i> , 2013, 112, 95-130.	2.0	38
36	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2012, 7, e48783.	2.5	37

#	ARTICLE	IF	CITATIONS
37	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α -synuclein oligomers. <i>Journal of Neurochemistry</i> , 2011, 117, 868-878.	3.9	60
38	Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alpha-Synuclein as Revealed by Ion Mobility Mass Spectrometry. <i>ChemBioChem</i> , 2011, 12, 2740-2744.	2.6	44
39	Inside Cover: Autoproteolytic Fragments Are Intermediates in the Oligomerization/Aggregation of the Parkinson's Disease Protein Alpha-Synuclein as Revealed by Ion Mobility Mass Spectrometry (ChemBioChem 18/2011). <i>ChemBioChem</i> , 2011, 12, 2706-2706.	2.6	0
40	An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4901-4905.	2.2	36
41	Baicalein reduces E46K α -synuclein aggregation <i>in vitro</i> and protects cells against E46K α -synuclein toxicity in cell models of familial Parkinsonism. <i>Journal of Neurochemistry</i> , 2010, 114, 419-429.	3.9	76
42	Seeding induced by α -synuclein oligomers provides evidence for spreading of α -synuclein pathology. <i>Journal of Neurochemistry</i> , 2009, 111, 192-203.	3.9	254
43	Antagonizing L-type Ca ²⁺ Channel Reduces Development of Abnormal Involuntary Movement in the Rat Model of L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia. <i>Biological Psychiatry</i> , 2009, 65, 518-526.	1.3	78
44	Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein microarrays. <i>Proteomics</i> , 2008, 8, 1980-1986.	2.2	33
45	Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins. <i>Neuroscience</i> , 2008, 154, 1450-1457.	2.3	29
46	The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of L-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease. <i>Journal of Neuroscience</i> , 2008, 28, 4311-4316.	3.6	83
47	Different Species of α -Synuclein Oligomers Induce Calcium Influx and Seeding. <i>Journal of Neuroscience</i> , 2007, 27, 9220-9232.	3.6	708
48	Guidelines for the preclinical <i>in vivo</i> evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2007, 8, 217-223.	2.1	98
49	Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. <i>Proteomics</i> , 2007, 7, 605-616.	2.2	122
50	The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity. <i>Journal of Neurochemistry</i> , 2007, 101, 1483-1490.	3.9	46
51	Functional protein kinase arrays reveal inhibition of p21-activated kinase 4 by α -synuclein oligomers. <i>Journal of Neurochemistry</i> , 2007, 103, 2401-2407.	3.9	18
52	Predominant Neuritic Pathology Induced by Viral Overexpression of α -Synuclein in Cell Culture. <i>Cellular and Molecular Neurobiology</i> , 2007, 27, 505-515.	3.3	20
53	Identification of a series of highly potent activators of the Nurr1 signaling pathway. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 193-196.	2.2	44
54	Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. <i>Nuclear Medicine and Biology</i> , 2006, 33, 607-614.	0.6	32

#	ARTICLE	IF	CITATIONS
55	Novel pharmacological targets for the treatment of Parkinson's disease. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 845-854.	46.4	262
56	Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)-2-Amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole Dihydrochloride]. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 189-199.	2.5	95
57	Genetic ablation of tumor necrosis factor- α and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. <i>Journal of Neurochemistry</i> , 2004, 89, 822-833.	3.9	183
58	Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2685-2691.	2.2	21
59	Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. <i>Behavioural Brain Research</i> , 2004, 154, 375-383.	2.2	34
60	Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. <i>Experimental Cell Research</i> , 2003, 288, 324-334.	2.6	146
61	Long-term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors. <i>Drug Development Research</i> , 2001, 52, 579-586.	2.9	19
62	CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2000, 362, 526-537.	3.0	48
63	RACK1 IS UP-REGULATED IN ANGIOGENESIS AND HUMAN CARCINOMAS. <i>FASEB Journal</i> , 2000, 14, 2549-2558.	0.5	107
64	Transgenic Activation of Ras in Neurons Promotes Hypertrophy and Protects from Lesion-Induced Degeneration. <i>Journal of Cell Biology</i> , 2000, 151, 1537-1548.	5.2	125
65	Design and synthesis of a biotinylated dopamine transporter ligand for the purification and labeling of dopaminergic neurons. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 261-266.	2.2	1
66	Position-independent expression of a human nerve growth factor-luciferase reporter gene cloned on a yeast artificial chromosome vector. <i>Nucleic Acids Research</i> , 1998, 26, 1826-1833.	14.5	5
67	Preparation of Magnetic Oligo(dT) Particles. <i>BioTechniques</i> , 1996, 20, 196-198.	1.8	10
68	Delayed emergence of effects of memory-enhancing drugs: implications for the dynamics of long-term memory.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 2041-2045.	7.1	46
69	Glucocorticoids and Neurotrophin Gene Regulation in the Nervous System. <i>Annals of the New York Academy of Sciences</i> , 1994, 746, 195-202.	3.8	18
70	In Vitro and in Vivo Methods for Evaluating Actions of Cytokines on Nerve Growth Factor Production in Central Nervous System. <i>Methods in Neurosciences</i> , 1993, 17, 37-60.	0.5	7
71	A rapid procedure for mRNA extraction from a large number of samples. <i>BioTechniques</i> , 1993, 14, 522-4.	1.8	11
72	Differential Regulation of Nerve Growth Factor (NGF) Synthesis in Neurons and Astrocytes by Glucocorticoid Hormones. <i>European Journal of Neuroscience</i> , 1992, 4, 404-410.	2.6	101

#	ARTICLE	IF	CITATIONS
73	Pretreatment with aldosterone or corticosterone blocks the memory-enhancing effects of nimodipine, captopril, CGP 37 849, and strychnine in mice. <i>Psychopharmacology</i> , 1992, 109, 383-389.	3.1	14
74	Molecular Mechanisms Leading to Lesion-Induced Increases in Nerve Growth Factor Synthesis. <i>Annals of the New York Academy of Sciences</i> , 1991, 633, 581-582.	3.8	10
75	The Synthesis of Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Hippocampal and Cortical Neurons Is Regulated by Specific Transmitter Systems. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 86-90.	3.8	56
76	Transforming growth factor- β 1 stimulates expression of nerve growth factor in the rat CNS. <i>NeuroReport</i> , 1990, 1, 9-12.	1.2	154
77	Glucocorticoid Hormones Negatively Regulate Nerve Growth Factor Expression In Vivo and in Cultured Rat Fibroblasts. <i>European Journal of Neuroscience</i> , 1990, 2, 795-801.	2.6	55
78	Lesion-induced increase in nerve growth factor mRNA is mediated by c-fos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 3899-3903.	7.1	292
79	Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. <i>EMBO Journal</i> , 1990, 9, 3545-50.	7.8	219
80	Molecular cloning and expression of brain-derived neurotrophic factor. <i>Nature</i> , 1989, 341, 149-152.	27.8	1,412
81	Interleukin 1 increases stability and transcription of mRNA encoding nerve growth factor in cultured rat fibroblasts. <i>Journal of Biological Chemistry</i> , 1988, 263, 16348-51.	3.4	195